What Are the Risk Factors for Ozempic-Related Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

If you've been taking Ozempic and are experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. This condition, characterized by delayed stomach emptying, has been increasingly reported in patients using GLP-1 receptor agonists. Building on decades of pharmacovigilance research, this page outlines the known risk factors and typical timeline for developing Ozempic-related gastroparesis, helping you make informed decisions about your health.

The Bridge: From Therapeutic Understanding to Post-Market Accountability

When a medication like Ozempic, originally developed for metabolic conditions, becomes associated with reports of gastroparesis—a condition affecting stomach motility—the informational landscape changes. Patients and their advocates now seek clarity on legal recourse, including the criteria for potential lawsuits. This pivot from general health literacy to targeted legal and medical guidance reflects a natural progression in how health information serves the public, addressing both therapeutic understanding and post-market accountability. The following sections provide a detailed examination of the medical evidence linking Ozempic to gastroparesis and the legal considerations for affected individuals.

Medical Evidence: Ozempic and Gastroparesis Risk

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its mechanism involves slowing gastric emptying, which can lead to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. The pharmacological action of Ozempic—delaying gastric emptying—can exacerbate or unmask gastroparesis in susceptible individuals. Mechanistically, GLP-1 receptor agonists like semaglutide inhibit gastric motility via vagal nerve pathways and direct effects on smooth muscle, potentially leading to prolonged gastric retention and gastroparesis-like symptoms. Evidence from clinical trials indicates that gastrointestinal adverse reactions occur significantly more frequently with Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight a dose-dependent increase in gastrointestinal symptoms, which may overlap with gastroparesis presentation.

Legal Context: Inadequate Warnings and Lawsuit Criteria

Regarding risk considerations, the adequacy of warnings for Ozempic and gastroparesis is a key issue. The prescribing information includes warnings about gastrointestinal adverse reactions but does not specifically list gastroparesis as a contraindication or warning. The label notes serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but gastroparesis is not explicitly addressed. This gap may affect patient awareness and physician monitoring. For affected patients, attorney-related considerations include evaluating whether the manufacturer provided adequate warnings about the risk of gastroparesis, especially given the known mechanism of delayed gastric emptying. The timeline between exposure and documented harm is critical: symptoms often emerge during dose escalation, as noted in clinical trials, but may persist or worsen with continued use. Patients who develop severe gastroparesis requiring hospitalization or long-term management may have grounds for legal action if they were not adequately informed of this risk. In summary, Ozempic use is associated with a higher incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic link through delayed gastric emptying is plausible, and clinical trial data show dose-dependent increases in such reactions. However, the prescribing information does not specifically warn about gastroparesis, which may be a factor in legal claims. Patients experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic should seek medical evaluation for gastroparesis and consult with an attorney to assess potential claims regarding inadequate warnings.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) works by slowing gastric emptying, which can cause or worsen gastroparesis, a condition where the stomach empties too slowly. Clinical trials show significantly higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo, including symptoms like nausea, vomiting, and abdominal pain that overlap with gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the criteria for an Ozempic gastroparesis lawsuit?

Potential lawsuit criteria include documented Ozempic use, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy, evidence that symptoms emerged or worsened after starting Ozempic, and proof that the manufacturer failed to provide adequate warnings about the risk of gastroparesis. Consulting with an attorney is recommended to evaluate individual cases.

Does the Ozempic label warn about gastroparesis?

No, the prescribing information for Ozempic does not specifically list gastroparesis as a warning or contraindication. It includes general gastrointestinal adverse reactions but does not explicitly address gastroparesis, which may be a factor in legal claims regarding inadequate warnings (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.